Who Supplies Itraconazole to India from JAPAN

To import finished pharmaceutical formulations containing Itraconazole into India, the foreign manufacturer must obtain a Registration Certificate from the Central Drugs Standard Control Organization (CDSCO). This involves submitting Form 40/41, along with a valid manufacturing license, Good Manufacturing Practice (GMP) certificate, and a Free Sale Certificate. The application is evaluated by the Drug Controller General of India (DCGI) to ensure compliance with safety, efficacy, and quality standards. The import license, issued by the Directorate General of Foreign Trade (DGFT), is valid for three years.

Imported Itraconazole formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, is mandatory. Customs drug inspectors conduct port inspections to verify documentation and sample collection. If a batch fails quality testing, it is subject to rejection or destruction as per regulatory procedures.

Between 2024 and 2026, CDSCO has implemented stricter regulations for imported medicines to prevent the sale of unapproved or illegal drugs in the Indian market. Import registration and licenses have become mandatory for all pharmaceutical imports, including finished formulations. The introduction of the Production Linked Incentive (PLI) scheme aims to boost domestic manufacturing, potentially impacting the volume of finished formulation imports.

India imports finished Itraconazole formulations primarily due to the availability of patented or branded products not manufactured domestically. Specific dosage forms, such as injectables or specialized tablets, may not be produced locally. The domestic market for Itraconazole formulations is substantial, with a total export value of $27.4 million across 285 exporters to 123 countries.

The import duty for Itraconazole formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Education Cess of 2%, a Secondary Higher Education Cess of 1%, and a Countervailing Duty (CVD) of 6%. The total landed duty amounts to 17.10%. There are no exemptions or concessional rates for imports from Japan.

India sources Itraconazole formulations from Japan due to the high quality and reliability of Japanese pharmaceutical products. Japan's adherence to stringent manufacturing standards and its ability to produce specialized dosage forms provide a competitive advantage. While other countries like China, Germany, and the US also supply Itraconazole formulations, Japan's share in the Indian market remains significant.

India imports Itraconazole formulations from Japan due to the availability of patented or branded products not manufactured domestically. Specific dosage forms, such as injectables or specialized tablets, may not be produced locally. The high quality and reliability of Japanese pharmaceutical products, along with adherence to stringent manufacturing standards, make Japan a preferred source.

Compared to other suppliers like China, Germany, and the US, Japan offers a competitive advantage in terms of product quality and reliability. Japanese manufacturers adhere to stringent quality control measures, ensuring high-quality products. While other countries may offer lower prices, Japan's reputation for quality and consistency justifies the higher cost for Indian importers.

Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, and potential shipping disruptions. Past shortages have occurred due to global supply chain challenges. To mitigate these risks, importers should consider diversifying suppliers and maintaining adequate inventory levels.

1. 1Diversify sourcing by identifying alternative suppliers to reduce dependency on a single source.
2. 2Implement robust inventory management practices to buffer against supply chain disruptions.
3. 3Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage financial risks.
4. 4Establish clear Minimum Order Quantities (MOQs) with suppliers to optimize procurement efficiency.
5. 5Conduct thorough supplier qualification processes, including audits and compliance checks, to ensure consistent product quality.

1. 1Obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT).
2. 2Register the manufacturing premises with CDSCO by submitting Form 40/41.
3. 3Obtain a Registration Certificate for the drug from CDSCO.
4. 4Secure an Import License from DGFT.
5. 5Engage a Customs House Agent (CHA) for customs clearance.
6. 6Seek an advance ruling for HS Code 30049099, if necessary.

1. 1Certificate of Analysis (CoA) for each batch.
2. 2Certificate of Pharmaceutical Product (CoPP).
3. 3Good Manufacturing Practice (GMP) certificate.
4. 4Drug Master File (DMF).
5. 5Stability data adhering to ICH Zone IVa/IVb guidelines.
6. 6Free Sale Certificate.
7. 7Manufacturer's authorization letter.

Upon arrival, CDSCO port inspectors collect samples for mandatory batch testing. The process includes sample collection, testing, and reporting, which may take several weeks. If a batch fails quality testing, it is subject to rejection or destruction as per regulatory procedures. Common quality issues from Japan may include discrepancies in labeling or packaging.

1. 1Renew CDSCO registration and import licenses annually.
2. 2Schedule periodic audits of Japanese manufacturing facilities.
3. 3Implement change control procedures for product modifications.
4. 4Establish pharmacovigilance systems for post-market monitoring.
5. 5Maintain detailed import records as per the Drug & Cosmetics Act.